Tracers / [177Lu]Lu-BL02
[177Lu]Lu-BL02
Also written as [Lu-177]Lu-BL02
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- CXCR4-targeting radioconjugate derived from LY2510924 (CXCR4 antagonist peptide/small molecule)
- Target / mechanism
- CXCR4 antagonist targeting CXCR4-expressing tumor cells PMID 42653659
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | custom manifold | SPE | >99% | >99% | BL02 Pepmic Co., Ltd., Suzhou, China | 42653659 2026 Pharmaceuticals (Basel) [177Lu]Lu-BL02 and [161Tb]Tb-BL02 were manually labeled with radiochemical conversions (RCC) exceeding 99% for both tracers on iTLC. — were manually labeled with radiochemical conversions (RCC) exceeding 99% for both tracers on iTLC |
Need this precursor?We can point you to suppliers for [177Lu]Lu-BL02, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42653659. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 42653659: 'In vivo biodistribution and pharmacokinetics were evaluated in MM.1S xenograft mouse models, supported by longitudinal SPECT imaging.'. | Stage 28: added indication(s) onc-myeloma from consolidated missing-rubric review.